Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | TAS1R3 | Q7RTX0 | 9/20 | 0.68 |
| ▸ | TAS1R1 | Q7RTX1 | 9/20 | 0.68 |
| ▸ | TAS1R2 | Q8TE23 | 8/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | CFD | P00746 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3775099 | 0.94 | TAS1R3 (0.62) | ALDH1A1TAS1R3TAS1R1TAS1R2LMNA | |
| SCHEMBL700730 | 0.81 | TAS1R3 (1.00) | ALDH1A1TAS1R3TAS1R1TAS1R2LMNA | |
| SCHEMBL700729 | 0.81 | TAS1R3 (1.00) | ALDH1A1TAS1R3TAS1R1TAS1R2LMNA | |
| SCHEMBL7615430 | 0.81 | APOB (0.58) | ALDH1A1TAS1R3TAS1R1TAS1R2LMNA | |
| SCHEMBL3775418 | 0.79 | ACKR3 (0.61) | LMNAKMT2AMEN1 | |
| SCHEMBL701855 | 0.78 | TAS1R3 (1.00) | ALDH1A1TAS1R3TAS1R1TAS1R2KMT2A | |
| SCHEMBL701854 | 0.78 | TAS1R3 (1.00) | ALDH1A1TAS1R3TAS1R1TAS1R2KMT2A | |
| SCHEMBL785465 | 0.78 | ALDH1A1 (0.72) | ALDH1A1TAS1R3TAS1R1TAS1R2LMNA | |
| SCHEMBL2817561 | 0.78 | ALDH1A1 (0.72) | ALDH1A1TAS1R3TAS1R1TAS1R2LMNA | |
| SCHEMBL788838 | 0.78 | ALDH1A1 (0.72) | ALDH1A1TAS1R3TAS1R1TAS1R2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | claimed |
| WO-2009103778-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2009-08-27 | — | — | WO | claimed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
| WO-2009103778-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | IL1B, LITAF, CYP11B1 | ALDH1A1 479/4885TAS1R3 3839/4885TAS1R1 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.